A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Biological: LVGN6051 Monoclonal Antibody InjectionBiological: toripalimab InjectionDrug: Paclitaxel injection
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Lyvgen Biopharma Holdings Limited
- Target Recruit Count
- 64
- Registration Number
- NCT06378177
- Locations
- 🇨🇳
Anhui Cancer Hospital, Hefei, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Combination Product: LVGN6051 and Anlotinib
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Lyvgen Biopharma Holdings Limited
- Target Recruit Count
- 65
- Registration Number
- NCT05301764
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hu Nan, China
🇨🇳Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
🇨🇳Henan cancer hospital, Zhenzhou, Henan, China
Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy
- Conditions
- Cancer
- Interventions
- Biological: LVGN7409
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Lyvgen Biopharma Holdings Limited
- Target Recruit Count
- 33
- Registration Number
- NCT05152212
- Locations
- 🇨🇳
Center Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Lyvgen Biopharma Holdings Limited
- Target Recruit Count
- 18
- Registration Number
- NCT04694781
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
- Conditions
- Cancer
- Interventions
- Biological: LVGN7409
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Lyvgen Biopharma Holdings Limited
- Target Recruit Count
- 126
- Registration Number
- NCT04635995
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
- Conditions
- Cancer
- Interventions
- Biological: LVGN6051Biological: KEYTRUDA® (pembrolizumab)
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Lyvgen Biopharma Holdings Limited
- Target Recruit Count
- 276
- Registration Number
- NCT04130542
- Locations
- 🇺🇸
University of California Irvine Health, Orange, California, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Verdi Oncology Research, Lafayette, Indiana, United States